Ascentage Pharma has unveiled its stellar first-half 2025 financial results, with sales revenue for its drug HQP1351® surging by an impressive 93% year-on-year to hit RMB 217 million. This remarkable growth is primarily fueled by the expansion of medical insurance coverage. Furthermore, the company's latest drug, Elevatis®, has secured approval for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma, marking it as the first domestically produced Bcl-2 inhibitor in China. Elevatis® has also embarked on global Phase III clinical studies. To bolster its commercialization efforts and research and development activities, Ascentage Pharma successfully completed a new share placement, raising RMB 1.37 billion. Currently, the company is progressing with nine registrational clinical trials, three of which have received approval from the U.S. Food and Drug Administration (FDA). On August 21, Ascentage Pharma will host an investor conference to provide in-depth insights into its first-half financial performance and future strategic directions.